The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
|Articles|December 1, 2012
Dermatology Times, Digital Edition, December 2012
Maximizing the Money : Amid increasing competition, group purchasing and similar programs allow dermatologists to do more with less Anti-fraud campaign could trigger wave of audits, experts warn Clinical Dermatology : Systemic options for severe atopic dermatitis continue to present challenges Cosmetic Dermatology : Uncovering the truth about antioxidants and how they work Cutaneous Oncology : Clinicopathologic correlation weeds out mimickers of lymphoma Practice Management : Document your E/M services correctly to obtain optimal reimbursement
Advertisement
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Advertisement
Advertisement
Trending on Dermatology Times
1
Galderma to Acquire ZO Skin Health for $1.5 Billion
2
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
3
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5